162 related articles for article (PubMed ID: 32510678)
1. Osteopontin, GLUT1 and Ki-67 expression in malignant peritoneal mesothelioma: prognostic implications.
Liu Y; Zheng G; Yang D; Guo X; Tian L; Song H; Liang Y
Intern Med J; 2021 Jun; 51(6):896-904. PubMed ID: 32510678
[TBL] [Abstract][Full Text] [Related]
2. IMP3 as a prognostic biomarker in patients with malignant peritoneal mesothelioma.
Hui S; Guo-Qi Z; Xiao-Zhong G; Chun-Rong L; Yu-Fei L; Dong-Liang Y
Hum Pathol; 2018 Nov; 81():138-147. PubMed ID: 30031101
[TBL] [Abstract][Full Text] [Related]
3. The Role of Ki-67 and Pre-cytoreduction Parameters in Selecting Diffuse Malignant Peritoneal Mesothelioma (DMPM) Patients for Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Kusamura S; Torres Mesa PA; Cabras A; Baratti D; Deraco M
Ann Surg Oncol; 2016 May; 23(5):1468-73. PubMed ID: 26572754
[TBL] [Abstract][Full Text] [Related]
4. Prognostic role of CD74, CD10 and Ki-67 immunohistochemical expression in patients with diffuse malignant peritoneal mesothelioma: a retrospective study.
Liang Y; Li C; Liu Y; Tian L; Yang D
BMC Cancer; 2023 May; 23(1):406. PubMed ID: 37147569
[TBL] [Abstract][Full Text] [Related]
5. Malignant peritoneal mesothelioma treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is GLUT1 expression a major prognostic factor? A preliminary study.
Hommell-Fontaine J; Isaac S; Passot G; Decullier E; Traverse-Glehen A; Cotte E; You B; Mohamed F; Gilly FN; Glehen O; Berger F
Ann Surg Oncol; 2013 Nov; 20(12):3892-8. PubMed ID: 23800898
[TBL] [Abstract][Full Text] [Related]
6. Survivin expression as an independent predictor of overall survival in malignant peritoneal mesothelioma.
Zhang G; Yang DL; Zheng G; Liang Y
Oncol Lett; 2020 Jun; 19(6):3871-3880. PubMed ID: 32382335
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical Evaluation of Minichromosome Maintenance Protein 7 (MCM7), Topoisomerase IIα, and Ki-67 in Diffuse Malignant Peritoneal Mesothelioma Patients Using Tissue Microarray.
Deraco M; Cabras A; Baratti D; Kusamura S
Ann Surg Oncol; 2015 Dec; 22(13):4344-51. PubMed ID: 25777091
[TBL] [Abstract][Full Text] [Related]
8. Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary study.
Bruno F; Baratti D; Martinetti A; Morelli D; Sottotetti E; Bonini C; Guaglio M; Kusamura S; Deraco M
Eur J Surg Oncol; 2018 Jun; 44(6):792-798. PubMed ID: 29503128
[TBL] [Abstract][Full Text] [Related]
9. The clinicopathological significance of TOP2A expression in malignant peritoneal mesothelioma.
Du X; Li X; Zhang B; Hao Z; Gao Y; Jiang X; Yang Z; Chen Y
Ann Diagn Pathol; 2023 Aug; 65():152155. PubMed ID: 37172528
[TBL] [Abstract][Full Text] [Related]
10. Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer.
Rouanne M; Adam J; Goubar A; Robin A; Ohana C; Louvet E; Cormier J; Mercier O; Dorfmüller P; Fattal S; de Montpreville VT; Lebret T; Dartevelle P; Fadel E; Besse B; Olaussen KA; Auclair C; Soria JC
BMC Cancer; 2016 Jul; 16():483. PubMed ID: 27422280
[TBL] [Abstract][Full Text] [Related]
11. CEA to peritoneal carcinomatosis index (PCI) ratio is prognostic in patients with colorectal cancer peritoneal carcinomatosis undergoing cytoreduction surgery and intraperitoneal chemotherapy: A retrospective cohort study.
Kozman MA; Fisher OM; Rebolledo BJ; Parikh R; Valle SJ; Arrowaili A; Alzahrani N; Liauw W; Morris DL
J Surg Oncol; 2018 Mar; 117(4):725-736. PubMed ID: 29266235
[TBL] [Abstract][Full Text] [Related]
12. Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma.
Hollevoet K; Nackaerts K; Gosselin R; De Wever W; Bosquée L; De Vuyst P; Germonpré P; Kellen E; Legrand C; Kishi Y; Delanghe JR; van Meerbeeck JP
J Thorac Oncol; 2011 Nov; 6(11):1930-7. PubMed ID: 21841505
[TBL] [Abstract][Full Text] [Related]
13. Impact of GLUT1 and Ki-67 expression on early‑stage lung adenocarcinoma diagnosed according to a new international multidisciplinary classification.
Maki Y; Soh J; Ichimura K; Shien K; Furukawa M; Muraoka T; Tanaka N; Ueno T; Yamamoto H; Asano H; Tsukuda K; Toyooka S; Miyoshi S
Oncol Rep; 2013 Jan; 29(1):133-40. PubMed ID: 23076555
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of Ki67 expression in malignant peritoneal mesothelioma.
Pillai K; Pourgholami MH; Chua TC; Morris DL
Am J Clin Oncol; 2015 Aug; 38(4):388-94. PubMed ID: 26214083
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic value of new TNM staging and serum CA125 in malignant peritoneal mesothelioma].
Wei F; Zheng GQ; Song H; Liang YF; Yin WJ; Sun NN; Yang YX
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2020 May; 38(5):321-326. PubMed ID: 32536066
[No Abstract] [Full Text] [Related]
16. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC).
Baratti D; Kusamura S; Cabras AD; Bertulli R; Hutanu I; Deraco M
Eur J Cancer; 2013 Oct; 49(15):3140-8. PubMed ID: 23831335
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological and prognostic significance of osteopontin expression in patients with prostate cancer: a systematic review and meta-analysis.
Yu A; Guo K; Qin Q; Xing C; Zu X
Biosci Rep; 2021 Aug; 41(8):. PubMed ID: 33635319
[TBL] [Abstract][Full Text] [Related]
18. CA 19-9 to peritoneal carcinomatosis index (PCI) ratio is prognostic in patients with epithelial appendiceal mucinous neoplasms and peritoneal dissemination undergoing cytoreduction surgery and intraperitoneal chemotherapy: A retrospective cohort study.
Kozman MA; Fisher OM; Rebolledo BJ; Valle SJ; Alzahrani N; Liauw W; Morris DL
Eur J Surg Oncol; 2017 Dec; 43(12):2299-2307. PubMed ID: 28993033
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of osteopontin expression in gastric cancer: a meta-analysis.
Gu X; Gao XS; Ma M; Qin S; Qi X; Li X; Sun S; Yu H; Wang W; Zhou D
Oncotarget; 2016 Oct; 7(43):69666-69673. PubMed ID: 27626167
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of second-line treatment and prognostic factors in patients with advanced malignant peritoneal mesothelioma: a retrospective study.
Kitadai R; Shimoi T; Sudo K; Noguchi E; Nagata Y; Sawada R; Takashima A; Boku N; Yonemori K
BMC Cancer; 2021 Mar; 21(1):294. PubMed ID: 33743636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
